Characterization of the differences in the cyclopiazonic acid binding mode to mammalian and P. Falciparum Ca2+ pumps: a computational study.
KAUST Grant NumberKUK-I1-012-43
MetadataShow full item record
AbstractDespite the investments in malaria research, an effective vaccine has not yet been developed and the causative parasites are becoming increasingly resistant to most of the available drugs. PfATP6, the sarco/endoplasmic reticulum Ca2+ pump (SERCA) of P. falciparum, has been recently genetically validated as a potential antimalarial target and cyclopiazonic acid (CPA) has been found to be a potent inhibitor of SERCAs in several organisms, including P. falciparum. In position 263, PfATP6 displays a leucine residue, whilst the corresponding position in the mammalian SERCA is occupied by a glutamic acid. The PfATP6 L263E mutation has been studied in relation to the artemisinin inhibitory effect on P. falciparum and recent studies have provided evidence that the parasite with this mutation is more susceptible to CPA. Here, we characterized, for the first time, the interaction of CPA with PfATP6 and its mammalian counterpart to understand similarities and differences in the mode of binding of the inhibitor to the two Ca2+ pumps. We found that, even though CPA does not directly interact with the residue in position 263, the presence of a hydrophobic residue in this position in PfATP6 rather than a negatively charged one, as in the mammalian SERCA, entails a conformational arrangement of the binding pocket which, in turn, determines a relaxation of CPA leading to a different binding mode of the compound. Our findings highlight differences between the plasmodial and human SERCA CPA-binding pockets that may be exploited to design CPA derivatives more selective toward PfATP6.
CitationDi Marino D, D’Annessa I, Coletta A, Via A, Tramontano A (2015) Characterization of the differences in the cyclopiazonic acid binding mode to mammalian and P. Falciparum Ca 2+ pumps: A computational study . Proteins: Structure, Function, and Bioinformatics 83: 564–574. Available: http://dx.doi.org/10.1002/prot.24734.
SponsorsGrant sponsor: King Abdullah University of Science and Technology (KAUST); Grant number: KUK-I1-012-43; Grant sponsor: PRIN; Grant number: 20108XYHJS; Grant sponsor: IIT Seed Project.
PubMed Central IDPMC4342768
CollectionsPublications Acknowledging KAUST Support
Except where otherwise noted, this item's license is described as This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
- Authors: Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S
- Issue date: 2010 Sep
- Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies.
- Authors: David-Bosne S, Florent I, Lund-Winther AM, Hansen JB, Buch-Pedersen M, Machillot P, le Maire M, Jaxel C
- Issue date: 2013 Nov
- The binding modes and binding affinities of artemisinin derivatives with Plasmodium falciparum Ca2+-ATPase (PfATP6).
- Authors: Naik PK, Srivastava M, Bajaj P, Jain S, Dubey A, Ranjan P, Kumar R, Singh H
- Issue date: 2011 Feb
- SERCA plays a crucial role in the toxicity of a betulinic acid derivative with potential antimalarial activity.
- Authors: Diedrich D, Wildner AC, Silveira TF, Silva GNS, Santos FD, da Silva EF, do Canto VP, Visioli F, Gosmann G, Bergold AM, Zimmer AR, Netz PA, Gnoatto SCB
- Issue date: 2018 May 1
- The Plasmodium falciparum Ca(2+)-ATPase PfATP6: insensitive to artemisinin, but a potential drug target.
- Authors: Arnou B, Montigny C, Morth JP, Nissen P, Jaxel C, Møller JV, Maire Ml
- Issue date: 2011 Jun